Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL

Blood

Volumn 121, Issue 11, 2013, Pages 1935-1943

  Rego, Eduardo M ^a   Kim, Haesook T ^b   Ruiz Argüelles, Guillermo J ^c   Undurraga, Maria Soledad ^d   Del Rosario Uriarte, Maria ^e   Jacomo, Rafael H ^a   Gutiérrez Aguirre, Homero ^f   Melo, Raul A M ^g   Bittencourt, Rosane ^h   Pasquini, Ricardo ⁱ   Pagnano, Katia ^j   Fagundes, Evandro M ^k   De Lourdes Chauffaille, Maria ^l   Chiattone, Carlos S ^m   Martinez, Lem ^e   Meillón, Luis A ⁿ   Gómez Almaguer, David ^f   Kwaan, Hau C ^o   Garcés Eisele, Javier ^c   Gallagher, Robert ^p   Niemeyer, Charlotte M ^q   Schrier, Stanley L ^r   Tallman, Martin ^s   Grimwade, David ^t   Ganser, Arnold ^u   Berliner, Nancy ^v   Ribeiro, Raul C ^w   Lo Coco, Francesco ^x,y   Löwenberg, Bob ^z   Sanz, Miguel A ^aa   more..

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Clinica Ruiz   (Mexico)

^d HOSPITAL DEL SALVADOR   (Chile)

^e Laboratorio de Biología Molecular Asociación Española Primera de Socorros Mutuos   (Uruguay)

^f HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^g Fundacao Hemope   (Brazil)

^h FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

ⁱ FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^j UNIVERSITY OF CAMPINAS   (Brazil)

^k FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^l FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^m FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

ⁿ INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^o NORTHWESTERN UNIVERSITY   (United States)

^p ALBERT EINSTEIN CANCER CENTER   (United States)

^q UNIVERSITY OF FREIBURG   (Germany)

^r STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^s WEILL CORNELL MEDICAL COLLEGE   (United States)

^t KING'S COLLEGE LONDON   (United Kingdom)

^u HANNOVER MEDICAL SCHOOL   (Germany)

^v HARVARD MEDICAL SCHOOL   (United States)

^w ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^x UNIVERSITY OF ROME TOR VERGATA   (Italy)

^y IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^z ERASMUS MEDICAL CENTER   (Netherlands)

^aa HOSPITAL UNIVERSITARIO LA FE   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYTARABINE; DAUNORUBICIN; IDARUBICIN; MITOXANTRONE; RETINOIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER REGRESSION; CAUSE OF DEATH; DEVELOPING COUNTRY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOFLUORESCENCE; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SOCIAL NETWORK; TREATMENT OUTCOME; YOUNG ADULT; BRAZIL; CHILE; COMMUNITY CARE; CONSENSUS; EVALUATION; INTERNATIONAL COOPERATION; MEXICO; MORTALITY; ORGANIZATION AND MANAGEMENT; PROGNOSIS; STATISTICS; SURVIVAL; TOTAL QUALITY MANAGEMENT; URUGUAY;

ADOLESCENT; ADULT; AGED; BRAZIL; CHILE; COMMUNITY NETWORKS; CONSENSUS; DEVELOPING COUNTRIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERNATIONALITY; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MEXICO; MIDDLE AGED; PROGNOSIS; QUALITY IMPROVEMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URUGUAY; YOUNG ADULT;

MLCS; MLOWN;

EID: 84876036212     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-449918     Document Type: Article

References (44)

1. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009; 113(9):1875-1891.
2. Tallman MS, Altman JK. Curative strategies in acute promyelocytic leukemia. Hematology (Am Soc Hematol Educ Program). 2008;2008(1):391-399.
3. Sanz MA, Montesinos P, Rayón C, et al; PETHEMA and HOVON Groups. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010;115(25): 5137-5146.
4. Adés L, Guerci A, Raffoux E, et al; European APL Group. Very long-term outcome of acute promyelocytic leukemia after treatment with alltrans retinoic acid and chemotherapy: the European APL Group experience. Blood. 2010; 115(9):1690-1696.
5. Ad és L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French- Belgian-Swiss and PETHEMA results. Blood. 2008;111(3):1078-1084.
6. Avvisati G, Lo-Coco F, Paoloni FP, et al; GIMEMA, AIEOP, and EORTC Cooperative Groups. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011; 117(18):4716-4725.
7. Fenaux P, Chastang C, Chevret S, et al; The European APL Group. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood. 1999;94(4):1192-1200.
8. Lo-Coco F, Avvisati G, Vignetti M, et al; Italian GIMEMA Cooperative Group. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010;116(17):3171-3179.
9. Sanz MA, Martín G, González M, et al. Programa de Estudio y Traitmiento de las Hemopatías Malignas. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004;103(4):1237-1243.
10. Sanz MA, Martín G, Rayón C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/ RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood. 1999;94(9):3015-3021.
11. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010;116(19):3751-3757.
12. de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111(7): 3395-3402.
13. Jácomo RH, Melo RA, Souto FR, et al. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica. 2007; 92(10):1431-1432.
14. Tallman MS, Manji GA. Don't just stand there, do something: strategies for the prevention of early death in acute promyelocytic leukemia: a commentary. Blood Cells Mol Dis. 2011;46(2): 173-174.
15. Falini B, Flenghi L, Fagioli M, et al. Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). Blood. 1997;90(10): 4046-4053.
16. Sanz MA, Lo-Coco F, MartÍn G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96(4): 1247-1253.
17. Sanz MA, Vellenga E, Rayón C, et al. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood. 2004;104(12):3490-3493.
18. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13(12): 1901-1928.
19. Frankel SR, Eardley A, Heller G, et al. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Ann Intern Med. 1994;120(4):278-286.
20. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competitive risk. Ann Stat. 1988;16(3):1141-1154.
21. Park MY, Hastie T. L1-regularized path algorithm for generalized linear models. J R Stat Soc Series B Methodol. 2007;69(4):659-677.
22. Tibshirani R. Regression shrinkage and selection via the LASSO: a retrospective. J R Stat Soc Series B Methodol. 2011;73(3):273-282.
23. Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997;16(4): 385-395.
24. Little RJA, Rubin DB. Statistical Analysis With Missing Data. New York: John Wiley & Sons; 2002.
25. Rubin DB. Inference and missing data. Biometrika. 1976;63(3):581-592.
26. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: John Wiley & Sons; 1987.
27. Ribeiro RC, Rego E. Management of APL in developing countries: epidemiology, challenges and opportunities for international collaboration. Hematology (Am Soc Hematol Educ Program). 2006;2006(1):162-168.
28. Santos FLS, Dore AI, Lima AS, et al. Hematological features and expression profile of myeloid antigens of acute promyelocytic leukemia patients: analysis of prognostic factors for development of the retinoic acid syndrome. Rev Assoc Med Bras. 2004;50(3):286-292.
29. De Botton S, Dombret H, Sanz M, et al; The European APL Group. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood. 1998;92(8): 2712-2718.
30. Douer D, Santillana S, Ramezani L, et al. Acute promyelocytic leukaemia in patients originating in Latin America is associated with an increased frequency of the bcr1 subtype of the PML/ RARalpha fusion gene. Br J Haematol. 2003; 122(4):563-570.
31. Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes- Núnẽz V, et al. More on geographic hematology: the breakpoint cluster regions of the PML/ RARalpha fusion gene in Mexican Mestizo patients with promyelocytic leukemia are different from those in Caucasians. Leuk Lymphoma. 2004;45(7):1365-1368.
32. Ruiz-Argüelles GJ, Morales-Toquero A, Gómez- Rangel JD, et al. Treatment of acute promyelocytic leukemia: a single institution experience. Rev Invest Clin. 2005;57(3):415-419.
33. Dimov ND, Medeiros LJ, Kantarjian HM, et al. Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients. Cancer. 2010;116(2): 369-376.
34. Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011;118(5): 1248-1254.
35. Lehmann S, Ravn A, Carlsson L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25(7):1128-1134.
36. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002;100(13): 4298-4302.
37. Ghavamzadeh A, Alimoghaddam K, Rostami S, et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol. 2011; 29(20):2753-2757.
38. Zhou J, Zhang Y, Li J, et al. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood. 2010;115(9):1697-1702.
39. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999;94(10):3315-3324.
40. Mathews V, George B, Chendamarai E, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol. 2010; 28(24):3866-3871.
41. Diverio D, Pandolfi PP, Rossi V, et al. Monitoring of treatment outcome in acute promyelocytic leukemia by RT-PCR. Leukemia. 1994;8(7): 1105-1107.
42. Gallagher RE, Yeap BY, Bi W, et al. Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood. 2003;101(7):2521-2528.
43. Grimwade D, Jovanovic JV, Hills RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol. 2009;27(22):3650-3658.
44. Lo-Coco F, Diverio D, Avvisati G, et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood. 1999;94(7):2225-2229.